FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
Top 100 pharma & biotech deals in 2022
The pandemic years haven’t been great for dealmaking. Our analysis of top 10 biopharma M&A tra
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-